Vanguard Global Advisers’s Pulmonx LUNG Stock Holding History

Vanguard Global Advisers’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.6K	Hold	13,559	–	–	﹤0.01%	3369
2026 Q1	$17.5K	Buy	+13,559	New	+$22.4K	﹤0.01%	3356

Other funds holding LUNG

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ECM

ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's LUNG Position: Q2 2026 in Review

Vanguard Global Advisers held its Pulmonx (LUNG) position steady in Q2 2026 at 13,559 shares worth $17.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3369.

Vanguard Global Advisers first reported a position in LUNG in Q1 2026 and has held it in 2 quarters since. 98 funds tracked by Wall St. Rank hold LUNG as of Q2 2026.

Vanguard Global Advisers held 13,559 shares of Pulmonx worth $17.6K as of Q2 2026.
Vanguard Global Advisers left its Pulmonx share count unchanged in Q2 2026.
Pulmonx made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3369 holding.
Vanguard Global Advisers first reported a position in Pulmonx in Q1 2026 and has held it in 2 quarters since.
98 funds tracked by Wall St. Rank held Pulmonx as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.